These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11435864)

  • 21. Benign positive margins after radical prostatectomy means a poor prognosis--con.
    Rubin MA; Montie JE
    Urology; 2005 Feb; 65(2):221-3. PubMed ID: 15708026
    [No Abstract]   [Full Text] [Related]  

  • 22. Incorrect biochemistry complicates prostate cancer management.
    McAuley I; Steinhoff G; McNeely M; Blood P
    Can J Urol; 2002 Apr; 9(2):1496-7. PubMed ID: 12010595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
    Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
    Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer.
    Morgan BR; Tarter TH
    J Urol; 2001 Dec; 166(6):2311-2. PubMed ID: 11696766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
    Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods.
    Yossepowitch O; Eggener SE; Bianco FJ; Carver BS; Serio A; Scardino PT; Eastham JA
    J Urol; 2007 Aug; 178(2):493-9; discussion 499. PubMed ID: 17561152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extremely high PSA (250ng/ml) in a patient with localised prostatic carcinoma.
    Colgan G; O'Brien MF; Ahmad I; Thornhill JA
    Ir Med J; 2005 Jan; 98(1):29. PubMed ID: 15782735
    [No Abstract]   [Full Text] [Related]  

  • 32. [Bone and bone marrow metastases of prostatic adenocarcinoma: the serum level of prostate-specific antigen may be normal].
    Marlier S; Durupt S; de Jaureguiberry JP; Marlier-Civatte M; Peybere B; Jaubert D
    Presse Med; 1996 May 4-11; 25(16):777. PubMed ID: 8692758
    [No Abstract]   [Full Text] [Related]  

  • 33. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
    J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
    Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
    Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone metastases from prostate cancer without elevated prostate-specific antigen levels: diagnosis by anti-PSA immunostaining.
    Berthelot JM; Gouin F; Denis M; Nomballais MF; Maugars Y; Blaive-Cervi S; Prost A
    Rev Rhum Engl Ed; 1995 Jan; 62(1):54-5. PubMed ID: 7540487
    [No Abstract]   [Full Text] [Related]  

  • 36. [Diagnostic value of tissue and serum prostate specific antigen in prostate cancer].
    Medvedev VL
    Voen Med Zh; 2004 Feb; 325(2):50-4. PubMed ID: 15101295
    [No Abstract]   [Full Text] [Related]  

  • 37. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ
    J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
    Xie W; Nakabayashi M; Regan MM; Oh WK
    Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors.
    Bloom KD; Richie JP; Schultz D; Renshaw A; Saegaert T; D'amico AV
    Urology; 2004 Feb; 63(2):333-6. PubMed ID: 14972484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.